IM Therapeutics

11001 West 120th Avenue
Suite 400
Broomfield
Colorado
80021
United States

Tel: 303-544-2104

Show jobs for this employer

About IM Therapeutics

IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen genes. The lead candidate drug is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes.

YEAR FOUNDED:
2015

LEADERSHIP:
Co-Founder and CEO: Steve Orndorff PhD
Scientific Co-Founder and CSO: Aaron Michels MD
Scientific Co-Founder and CMO: Peter Gottlieb MD
COO and CFO: Greg Kading

7 articles with IM Therapeutics